Since 2012, Dr. Aivado has served as Aileron’s senior vice president and chief medical and scientific officer.  He succeeds John P. Longenecker, PhD, who was appointed interim chief executive officer on May 15, 2018. 

“We are very pleased to announce this well-deserved promotion for Dr. Aivado,” said Aileron Chairman Jeff Bailey.  “Manuel clearly best exemplifies the skill set and talent needed to lead the company through its next stage of development.” 

“I am very excited to take on this new responsibility at Aileron as we further expand the clinical development of our lead product candidate, ALRN-6924, into combination therapies.  ALRN-6924 represents the proof-of-concept for Aileron’s stapled peptide technology, which I believe to be capable of producing additional novel drug candidates that address previously undruggable targets,” said Dr. Aivado. “In the future, we plan to broaden the applicability of our technology and expand our external collaborations.  I am pleased with the external recognition that ALRN-6924 and our stapled peptide technology have earned in the scientific community, and I look forward to additional collaborations translating this recognition into therapeutic and commercial success.”